383-19-7

Usage

Uses

Used in Synthetic Organic Chemistry:
2,2-Difluoro-2-phenylacetamide is used as a building block for creating more complex organic materials. Its high reactivity, due to the presence of a fluorine atom and the phenyl group, makes it a valuable compound in the synthesis of various organic compounds.
Used in Pharmaceutical Industry:
2,2-Difluoro-2-phenylacetamide is used as a starting material for the synthesis of pharmaceutical compounds. Its unique structure and reactivity allow for the development of new drugs with potential therapeutic applications.
Used in Material Science:
2,2-Difluoro-2-phenylacetamide is used in the development of new materials with specific properties. Its strong carbon-fluorine bonds and aromatic characteristics contribute to the creation of materials with enhanced stability and reactivity.

InChI:InChI=1/C8H7F2NO/c9-8(10,7(11)12)6-4-2-1-3-5-6/h1-5H,(H2,11,12)

Upstream product

• 2002-72-4 α,α-difluorobenzeneacetonitrile 
• 40626-45-7 α,α-dichlorobenzylcyanide 
• 591-50-4 iodobenzene 
• 2169-67-7 2-bromo-2,2-difluoroacetamide 
• 28557-00-8 phenylzinc chloride 
• 1603-79-8 phenylglyoxylic acid ethyl ester 

Downstream Products

• 55601-21-3 2,2-difluoro-2-phenylethylamine 
• 39625-10-0 2,2-difluoro-2-phenylethanamine hydrochloric acid salt 
• 885068-32-6 (6-chloro-2-methoxy-pyrimidin-4-yl)-(2,2-difluoro-2-phenyl-ethyl)-amine 
• 650-93-1 2,2-difluoro-2-(3-nitrophenyl)acetic acid 
• 339-30-0 2,2-difluoro-N-2-diphenylacetamide 
• 2248-46-6 ethyl 2,2-difluoro-2-phenylacetate 
• 402-03-9 (3-amino-phenyl)-difluoro-acetic acid 
• 312-24-3 difluoro-phenyl-acetyl chloride 
• 2002-72-4 α,α-difluorobenzeneacetonitrile 
• 360-03-2 2,2-Difluoro-2-phenylacetic acid 

Relevant academic research and scientific papers

Direct Approach to 3-Fluoroindoles and 3,3-Difluoroindolines from 2,2-Difluoro-2-phenylethan-1-amines via C-H/N-H Coupling

Herein, a direct method for the synthesis of 3-fluoroindoles and 3,3-difluoroindolines from easily accessible 2,2-difluoro-2-phenyl ethan-1-amines is presented. This protocol was performed by Pd-catalyzed direct C-H/N-H coupling and employed picolinamide as a directing group. By controlling the temperature for this transformation, various 3,3-difluoroindolines and 3-fluoroindoles could be isolated with moderate to good yields.

Nickel-Catalyzed Negishi Cross-Coupling of Bromodifluoroacetamides

A nickel-catalyzed Negishi coupling of bromodifluoroacetamides with arylzinc reagents has been developed. This reaction allows access to difluoromethylated aromatic compounds containing a variety of aryl groups and amide moieties. Furthermore, highly effe

A COMBINATION OF NIACIN AND A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST

The present invention is directed to a pharmaceutical composition comprising Niacin or a pharmaceutically acceptable salt, solvate or N-oxide thereof, or a nicotinic acid receptor agonist, and a compound of formula (I) as defined herein, or an N-oxide thereof, or an ester prodrug thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and its use for treating atherosclerosis, dyslipidemia, diabetes or a related condition while reducing substantial flushing.

1,3-DISUBSTITUTED HETEROARYL NMDA/NR2B ANTAGONISTS

Compounds represented by Formula I: (wherein A, B, D, P, Q, R1, R2, R3, W and Y are described herein) or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological co

2, 6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIDIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS

The present invention is directed a compound of Formula (I) as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, discorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).

Cyclic oxyguanidine pyrazinones as protease inhibitors

Cyclic oxyguanidine pyrazinone compounds are described, including compounds of the Formula I: wherein R3, R4, R5, W, and A are as set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable

Substituted biphenyl isoxazole sulfonamides

Compounds of the formula STR1 inhibit the activity of endothelin. The symbols are defined as follows: R1, R2, R3 and R4 are each directly bonded to a ring carbon and are each independently (a) hydrogen; (b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl or aralkoxy, any of which may be substituted with Z1, Z2 and Z3 ; (c) halo; (d) hydroxyl; (e) cyano; (f) nitro; (g) --C(O)H or --C(O)R5 ; (h) --CO2 H or --CO2 R5 ; (i) --Z4 --NR6 R7 ; (j) --Z4 --N(R10)--Z5 --NR8 R9 ; or (k) R3 and R4 together may also be alkylene or alkenylene, either of which may be substituted with Z1, Z2 and Z3, completing a 4- to 8-membered saturated, unsaturated or aromatic ring together with the carbon atoms to which they are attached; and the remaining symbols are as defined in the specification.

&α,&α-Difluoroarylacetic Acids: Preparation from (Diethylamino)sulfur Trifluoride and &α-Oxoarylacetates

Several α,α-difluoroarylacetic acids have been prepared by reaction of DAST ((diethylamino)sulfur trifluoride) with esters of α-oxoarylacetic acids and then hydrolysis of the resulting difluoro ester.Examples include the α,α-difluoro derivates of the synthetic plant auxin, α-naphthylacetic acid, and the antiinflammatory drug, ibufenac.